Laboratory Evaluation of Persistent Leukopenia
For persistent leukopenia, obtain a complete blood count (CBC) with manual differential, peripheral blood smear review, and bone marrow aspiration with biopsy including cytogenetics, flow cytometry, and molecular testing if cytopenias persist or worsen over 2-4 weeks.
Initial Assessment
Start with a CBC with manual differential and peripheral blood smear review 1, 2. The peripheral blood smear is essential—it reveals dysplasia, blast cells, and morphologic abnormalities that automated counts miss 1, 3. This should be interpreted by an experienced hematopathologist, not just flow cytometry, as flow cannot replace morphologic assessment 4.
Key Elements to Evaluate:
- Duration of cytopenia: Stable cytopenia for at least 6 months suggests myelodysplastic syndrome (MDS), though only 2 months is needed if accompanied by specific karyotype or bilineage dysplasia 1
- Single versus multiple lineages: Isolated neutropenia has different implications than pancytopenia 5, 6
- Absolute neutrophil count (ANC): Severe neutropenia (<0.5 × 10⁹/L) requires urgent evaluation 5, 6
- Mean corpuscular volume (MCV): Macrocytosis can indicate MDS 7
Follow-Up Testing Algorithm
If initial CBC shows persistent or worsening cytopenia:
Repeat CBC within 2-4 weeks 7. If abnormalities persist or worsen across two or more measurements, proceed immediately to bone marrow evaluation 7.
Bone Marrow Examination
Bone marrow aspiration and biopsy are mandatory for persistent unexplained leukopenia with the following components 8, 1, 2:
Required Studies:
Morphologic assessment: Aspirate smears and core biopsy to evaluate:
Conventional cytogenetics (karyotype): This is non-negotiable and cannot be replaced by FISH or molecular testing 8, 2. Specific abnormalities like del(5q), del(20q), +8, or -7/del(7q) are diagnostic for MDS even with <5% blasts 1, 4.
Flow cytometry immunophenotyping: Sufficient panel to distinguish acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and lineage ambiguity 8. Also assess CD34+ cells and evaluate for paroxysmal nocturnal hemoglobinuria (PNH) clone 1.
Molecular genetic testing: Include FLT3, NPM1, CEBPA, IDH1/IDH2, RUNX1, ASXL1, TP53, and KIT mutations 2. These guide prognosis and treatment decisions.
FISH testing: Complements but does not replace conventional cytogenetics 8.
Additional Laboratory Studies
Obtain these screening tests concurrently 1:
- Serum erythropoietin
- Vitamin B12 and RBC folate levels
- Serum ferritin (with serum iron and total iron binding capacity if inflammatory conditions present)
- Lactate dehydrogenase (LDH) 2
- Comprehensive metabolic panel 2
- HIV screening if clinically indicated 1
For specific populations:
- Young patients with hypoplastic MDS and normal cytogenetics: Screen for PNH (flow cytometry for CD55/CD59) and HLA-DR15 to identify candidates for immunosuppressive therapy 1
- Children or young adults: Consider germ line testing for inherited bone marrow failure syndromes 7, 9
- Transplant candidates: HLA typing (A, B, C, DR, DQ) and CMV status 1
Critical Pitfalls to Avoid
- Do not rely solely on automated differentials—manual review is mandatory 1, 4
- Do not use flow cytometry blast percentages for prognosis—only morphologic assessment counts 1
- Do not skip conventional cytogenetics even if molecular testing is available 8, 2
- Do not delay bone marrow examination if counts worsen or remain abnormal over 2-4 weeks 7
- Exclude reversible causes first: Recent growth factors, transfusions, medications, infections, nutritional deficiencies 8, 10
Monitoring Frequency
- High-risk conditions (e.g., Fanconi anemia, known MDS): CBC every 3-4 months even if stable 7
- Other conditions with stable counts: CBC every 6-12 months 7
- Any new or worsening cytopenia: Repeat CBC in 2-4 weeks 7
- High-risk MDS patients: Annual bone marrow with cytogenetics 7
This algorithmic approach prioritizes early detection of malignant transformation while avoiding unnecessary invasive testing in benign conditions 10, 11.